NCT07158697 Health Chat for Empowerment-based Lifestyle Planning for Cardiometabolic Multimorbidity
| NCT ID | NCT07158697 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Hong Kong |
| Condition | Cardiometabolic Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 232 participants |
| Start Date | 2025-09-08 |
| Primary Completion | 2027-02-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 232 participants in total. It began in 2025-09-08 with a primary completion date of 2027-02-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to: 1. assess the feasibility, acceptability, and the preliminary effects of the health chat for empowerment-based lifestyle planning for CMM (HcELP\_CMM); 2. examine the short-term effects of the HcELP\_CMM program on lifestyle behaviors, cardiometabolic indicators, symptom burden, health related quality of life (HRQoL), psychological well-being, and physical function in patients with CMM; 3. examine the long-term effects of the HcELP\_CMM program on lifestyle behaviors, cardiometabolic indicators, symptom burden, HRQoL, psychological well-being, and physical function in patients with CMM. The main questions it aims to answer are: 1. If the HcELP\_CMM program is feasible and acceptable? 2. If the HcELP\_CMM program has the potential to improve the lifestyle behaviors, cardiometabolic indicators, symptom burden, HRQoL, psychological well-being, and physical function in patients with CMM compared to the usual care group in the short-term？ 3. If the HcELP\_CMM program has the potential to improve the lifestyle behaviors, cardiometabolic indicators, symptom burden, HRQoL, psychological well-being, and physical function in patients with CMM compared to the usual care group in the long-term？
Eligibility Criteria
Inclusion Criteria: 1. Adults aged 18 years or above； 2. Diagnosed with cardiometabolic multimorbidity (CMM), which was defined as co-existing with two or more cardiometabolic diseases, including primary hypertension, type 2 diabetes, stroke, heart diseases (eg. coronary heart disease, arrhythmia, heart failure, myocardial infarction, and cardiac valve diseases), dyslipidemia, and obesity; 3. Possessed a digital device installed with WeChat, as well as with an internet connection. Exclusion Criteria: 1. Contraindications to exercise according to American College of Sports Medicine (ACSM), such as severe musculoskeletal disorders, severe cardiovascular diseases, or spinal nerve injury; 2. Diagnosis of psychiatric disease; 3. Has impaired cognitive function as indicated by an Abbreviated Mental Test Score (AMTS) ≤6; 4. Has impaired sensory or communication function which hider them participation in this program, such as hearing loss, vision loss, and unable to speak Mandarin.
Contact & Investigator
Jing Xi, PhD
PRINCIPAL INVESTIGATOR
The University of Hong Kong
Frequently Asked Questions
Who can join the NCT07158697 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiometabolic Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07158697 currently recruiting?
Yes, NCT07158697 is actively recruiting participants. Contact the research team at u3010484@connect.hku.hk for enrollment information.
Where is the NCT07158697 trial being conducted?
This trial is being conducted at Suzhou, China, Suzhou, China, Suzhou, China.
Who is sponsoring the NCT07158697 clinical trial?
NCT07158697 is sponsored by The University of Hong Kong. The principal investigator is Jing Xi, PhD at The University of Hong Kong. The trial plans to enroll 232 participants.